
CLAIMS


1. 3’-Deoxyadenosine-5’-O-[phenyl(benzyloxy-L-alaninyl)] phosphate



,

or a pharmaceutically acceptable salt, ester, salt of an ester, or solvate of the compound thereof.

2. 3’-Deoxyadenosine-5’-O-[phenyl(benzyloxy-L-alaninyl)] phosphate according to claim 1



.

3. A compound according to claim 1 or claim 2 for use as a medicament.

4. A compound according to claim 1 or claim 2 for use in the prophylaxis or treatment of cancer.

5. A compound for use according to claim 4 for use in targeting cancer stem cells in the treatment of cancer.

6. A compound for use according to claim 5, wherein the cancer is selected from leukaemia, lymphoma, breast cancer, lung cancer, colon cancer, prostate cancer, ovarian cancer, skin cancer, bladder cancer, biliary cancer and pancreatic cancer.

7. A compound for use according to claim 5, wherein the cancer is selected from breast cancer, CNS cancer, colon cancer, Ewing's sarcoma, melanoma, liver cancer, cholangiocarcinoma, ovarian cancer, pancreatic cancer, non small cell lung cancer, bladder cancer, acute myeloid leukaemia, B-acute lymphoblastic leukaemia, B-acute lymphoblastic leukaemia, multiple myeloma and T-acute lymphoblastic leukaemia.

8. A compound for use according to claim 4 wherein the cancer is selected from the group consisting of: leukaemia, lymphoma, multiple myeloma, lung cancer (including non small cell lung cancer and small cell lung cancer), liver cancer, breast cancer, bladder cancer, prostate cancer, head and neck cancer, neuroblastoma, sarcoma (including Ewing's sarcoma), thyroid carcinoma, skin cancer (including melanoma), oral squamous cell carcinoma, urinary bladder cancer, Leydig cell tumour, biliary cancer, such as cholangiocarcinoma or bile duct cancer, pancreatic cancer, colon cancer, colorectal cancer and gynaecological cancers, including ovarian cancer, endometrial cancer.

9. The compound for use according to claim 8 wherein the cancer is leukaemia or lymphoma.

10. The compound for use according to claim 9 wherein the leukaemia is selected from the group comprising acute lymphoblastic leukaemia, acute myelogenous leukaemia, acute promyelocytic leukaemia, acute lymphocytic leukaemia, chronic myelogenous leukaemia, chronic lymphocytic leukaemia, monoblastic leukaemia, hairy cell leukaemia, Hodgkin lymphoma and non-Hodgkin lymphoma.

11. The compound for use according to claim 10 wherein the leukaemia is acute lymphoblastic leukaemia.

12. A compound for use according to any one of claims 4 to 11, wherein the cancer is relapsed or refractory cancer.

13. A compound for use according to any one of claims 4 to 11, wherein the cancer is a metastatic cancer.

14. A pharmaceutical composition comprising a compound according to claim 1 or claim 2 in combination with a pharmaceutically acceptable carrier, diluent or excipient.